Piper Sandler Reiterates Overweight Rating on Arrowhead Pharma (ARWR)

Piper Sandler analyst Edward A. Tenthoff reiterated an Overweight rating and $62.00 price target on Arrowhead Pharma (NASDAQ: ARWR).

The analyst commented, "Arrowhead filed the NDA for plozasiran in Familial Chylomicronemia Syndrome (FCS), which could result in the company's first approval and launch in 2025. At AHA, Arrowhead presented Phase III PALISADE data showing 25mg q3M plozasarian met the primary endpoint reducing triglycerides by 80% in FCS patients at 10 months (p<0.001) and risk of acute pancreatitis by 83%. (p=0.029) Also at AHA, Phase II MUIR and SHASTA-2 OLE data showed TG reductions of 73% and 86% maintained out to 15 months with favorable changes in other lipid markers and no changes in LDLc or Lp(a). Arrowhead is conducting the Phase III SHASTA-3 and SHASTA-4 trials in SHTG, MUIR-3 trial in HGT, and is planning the CAPITAN CVOT trial to broaden the plozasiran label. Arrowhead has pro forma cash of ~$837 million excluding FY4Q:24 burn. We reiterate our Overweight rating."

For an analyst ratings summary and ratings history on Arrowhead Pharma click here. For more ratings news on Arrowhead Pharma click here.

Shares of Arrowhead Pharma closed at $19.02 yesterday.

You May Also Be Interested In

• Morgan Stanley Upgrades Telecom Argentina (TEO) to Overweight
• Freshpet co-founder Morris to step back as Baty takes president role
• Lenovo expands hybrid AI portfolio with new inferencing platforms